Evan Kearns's most recent trade in Cogent Biosciences Inc was a trade of 230,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 23, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 230,000 | 230,000 | - | - | Stock Option (Right to Buy) | |
Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 255,000 | 255,000 | - | - | Stock Option (Right to Buy) | |
Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
Cogent Biosciences Inc | Evan Kearns | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 202,250 | 202,250 | - | - | Stock Option (Right to Buy) | |
Agenus Inc | Evan Kearns | VP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2020 | 150,000 | 150,000 | - | - | Stock Option (Right to buy) |